A number of therapeutic agents including CAR-T cells, CAR-NK cells, bispecific T-cell engagers, and bispecific innate cell engagers – all of which are currently being investigated in preclinical and clinical studies - exploit approaches to harness effectors of the adaptive or innate immune system in order to bridge them with the tumor cell-surface EGFR and prime them for destruction of the EGFR-expressing cancer cells (28, 29). The gene discussed is EGFR; the disease is cancer.